☰

Derek W. Bartlett, Ph.D. - Publications

Affiliations: 
2007 Chemical Engineering California Institute of Technology, Pasadena, CA 
Area:
Catalysis, Molecular Therapy
Tree Info Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Molecular Pharmaceutics. 11: 3965-73. PMID 24779727 DOI: 10.1021/Mp500164R  0.302
2014 Olafsen T, Bartlett D, Ho D, Zhang G, Torgov M, Keppler J, Behrenbruch C, Wu A, Pandit-Taskar N, Morris MJ, Lewis JS, Lyashchenko SK, Gudas JM. Minibody imaging of prostate-specific membrane antigen (PSMA): From concept to clinic. Journal of Clinical Oncology. 32: e16057-e16057. DOI: 10.1200/Jco.2014.32.15_Suppl.E16057  0.38
2013 Gudas J, Olafsen T, Ho D, Bartlett D, Lipman A, Sorenson K, Keppler J, Behrenbruch C, Wu A, Ashworth S, Passchier J, Gunn R, Matthews P. Abstract LB-351: Evaluation of two engineered antibody fragments derived from a human CD20 antibody as tracers for immunoPET . Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-351  0.364
2008 Bartlett DW, Davis ME. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnology and Bioengineering. 99: 975-85. PMID 17929316 DOI: 10.1002/Bit.21668  0.605
2007 Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proceedings of the National Academy of Sciences of the United States of America. 104: 15549-54. PMID 17875985 DOI: 10.1073/Pnas.0707461104  0.559
2007 Heidel JD, Liu JY, Yen Y, Zhou B, Heale BS, Rossi JJ, Bartlett DW, Davis ME. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2207-15. PMID 17404105 DOI: 10.1158/1078-0432.Ccr-06-2218  0.684
2007 Bartlett DW, Davis ME. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjugate Chemistry. 18: 456-68. PMID 17326672 DOI: 10.1021/Bc0603539  0.54
2007 Bartlett DW, Davis ME. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnology and Bioengineering. 97: 909-21. PMID 17154307 DOI: 10.1002/Bit.21285  0.524
2007 Bartlett DW, Davis ME. Characterization and in vivo efficacy of targeted nanoparticles for systemic siRNA delivery to tumors 2007 Nsti Nanotechnology Conference and Trade Show - Nsti Nanotech 2007, Technical Proceedings. 2: 763-766.  0.516
2006 Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1606-14. PMID 16533788 DOI: 10.1158/1078-0432.Ccr-05-1566  0.67
2006 Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Research. 34: 322-33. PMID 16410612 DOI: 10.1093/Nar/Gkj439  0.577
2006 Bartlett DW, Davis ME. 705. A Practical Approach to siRNA-Based Treatment Design Using Bioluminescent Imaging and Mathematical Modeling Molecular Therapy. 13: S272-S273. DOI: 10.1016/J.Ymthe.2006.08.784  0.575
2005 Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Research. 65: 8984-92. PMID 16204072 DOI: 10.1158/0008-5472.Can-05-0565  0.707
2005 Bartlett DW, Heidel JD, Davis ME. 208. Physicochemical and Biological Characterization of Cyclodextrin-Based Polycation (CDP)/siRNA Composites Designed for Systemic Delivery Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.211  0.656
2005 Heidel JD, Hu-Lieskovan S, Bartlett DW, Triche TJ, Davis ME. 70. Systemic Administration of siRNA Against EWS-FLI1 Using a Targeted, Non-Viral Formulation Inhibits Growth in a Disseminated Murine Model of Ewing's Sarcoma Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.048  0.697
Show low-probability matches.